Trial · NCT07228390
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo. | Week 16 | The difference in proportion of responders based on HiSCR50 response at Week 16 in patients with HS treated with ritlecitinib versus placebo. |
| Secondary | Proportion of participants achieving HiSCR50 response | at Weeks 1, 2, 4, 6, 8 and Week 12. | The difference in proportion of responders based on HiSCR50 response at Weeks 1, 2, 4, 6, 8 and 12 in patients with HS treated with ritlecitinib versus placebo |
| Secondary | Proportion of participants achieving HiSCR75 response | at Weeks 1, 2, 4, 6, 8, 12 and Week 16. | The difference in proportion of responders based on HISCR75 response at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib versus placebo |
| Secondary | Proportion of participants achieving HiSCR90 response | at Weeks 1, 2, 4, 6, 8, 12 and Week 16 | The difference in proportion of responders based on HiSCR90 response at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib versus placebo |
| Secondary | Response based on a on total abscess and inflammatory nodule count (AN Count) of 0 or 1 | Week 16 | The difference in proportion of responders based on a total AN count of 0 or 1 at Week 16 in patients with HS treated with ritlecitinib and placebo |
| Secondary | Response based on a total AN count of 0, 1, or 2 | At week 16 | The difference in proportion of responders based on a total AN count of 0, 1 or 2 at Week 16 in patients with HS treated with ritlecitinib and placebo. |
| Secondary | Percent change from Baseline(CFB) in total AN count | Weeks 1, 2, 4, 6, 8, 12 and 16. | The difference in mean percent CFB in total AN count at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo |
| Secondary | Absolute score in Hidradenitis Suppurativa Investigator Global Assessment (HS-IGA) | at Weeks 1, 2, 4, 6, 8, 12 and 16 | The difference in mean absolute score in HS-IGA at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo |
| Secondary | CFB in Hidradenitis Suppurativa Investigator Global Assessment (HS-IGA) | at Weeks 1, 2, 4, 6, 8, 12 and 16 | Mean CFB in HS-IGA at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo |
| Secondary | Proportion of participants achieving a HS-IGA=0 or 1 | Weeks 1, 2, 4, 6, 8, 12 and 16 | The difference in proportion of responders based on HS-IGA=0 or 1 at Weeks 1, 2, 4, 6, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo |
| Secondary | Participants who experience an HS flare, defined as at least a 25% increase in total AN count with a minimum increase of 2 relative to Baseline | Weeks 4, 8, 12 and 16. | The difference in proportion of HS flare at Weeks 4, 8, 12 and 16 in patients with HS treated with ritlecitinib and placebo |
| Secondary | CFB in Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) | Weeks 1, 2, 4, 6, 8, 12 and 16 | |
| Secondary | Skin pain NRS30 (numeric rating scale) response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3 | Weeks 1, 2, 4, 6, 8, 12, and 16 | |
| Secondary | Percent CFB in skin pain NRS, at worst and on average, respectively, in participants with baseline skin pain NRS ≥3 | Weeks 1, 2, 4, 6, 8, 12, and 16 | |
| Secondary | CFB in skin pain NRS, at worst and on average, respectively | at Weeks 1, 2, 4, 6, 8, 12, and 16 | |
| Secondary | Skin pain NRS50 response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3. | at Weeks 1, 2, 4, 6, 8, 12, and 16 | |
| Secondary | Skin pain NRS70 response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3 | at Weeks 1, 2, 4, 6, 8, 12, and 16, | |
| Secondary | Incidence of treatment emergent adverse events (TEAE), adverse events (AE) and serious adverse events (SAE) leading to discontinuation | up to 24 Weeks | |
| Secondary | Incidence of clinically significant laboratory abnormalities over time | up to 24 Weeks | |
| Secondary | Absolute score and CFB in Hidradenitis Suppurativa Quality of Life (HiSQOL) | at Weeks 1, 2, 4, 6, 8, 12 and 16. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07228390/registered